Production Engineering Department (Formulation Technology), Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Drug Dev Ind Pharm. 2012 Oct;38(10):1254-61. doi: 10.3109/03639045.2011.645832. Epub 2012 Feb 17.
To design a high drug loading formulation of self-microemulsifying/micelle system.
A poorly-soluble model drug (CH5137291), 8 hydrophilic surfactants (HS), 10 lipophilic surfactants (LS), 5 oils, and PEG400 were used. A high loading formulation was designed by a following stepwise approach using a high-throughput formulation screening (HTFS) system: (1) an oil/solvent was selected by solubility of the drug; (2) a suitable HS for highly loading was selected by the screenings of emulsion/micelle size and phase stability in binary systems (HS, oil/solvent) with increasing loading levels; (3) a LS that formed a broad SMEDDS/micelle area on a phase diagram containing the HS and oil/solvent was selected by the same screenings; (4) an optimized formulation was selected by evaluating the loading capacity of the crystalline drug. Aqueous solubility behavior and oral absorption (Beagle dog) of the optimized formulation were compared with conventional formulations (jet-milled, PEG400).
As an optimized formulation, d-α-tocopheryl polyoxyethylene 1000 succinic ester: PEG400 = 8:2 was selected, and achieved the target loading level (200 mg/mL). The formulation formed fine emulsion/micelle (49.1 nm), and generated and maintained a supersaturated state at a higher level compared with the conventional formulations. In the oral absorption test, the area under the plasma concentration-time curve of the optimized formulation was 16.5-fold higher than that of the jet-milled formulation.
The high loading formulation designed by the stepwise approach using the HTFS system improved the oral absorption of the poorly-soluble model drug.
设计一种高载药自微乳/胶束系统。
使用一种难溶性模型药物(CH5137291)、8 种亲水表面活性剂(HS)、10 种亲脂性表面活性剂(LS)、5 种油和聚乙二醇 400(PEG400)。通过使用高通量制剂筛选(HTFS)系统的逐步方法设计高载药制剂:(1)通过药物溶解度选择油/溶剂;(2)通过在二元系统(HS、油/溶剂)中筛选乳液/胶束粒径和相稳定性,随着载药量的增加选择适合高载药的 HS;(3)通过相同筛选,在包含 HS 和油/溶剂的相图上选择形成广泛 SMEDDS/胶束区域的 LS;(4)通过评估结晶药物的载药量选择优化制剂。比较优化制剂的水溶解度行为和口服吸收(比格犬)与常规制剂(喷射研磨,PEG400)。
作为一种优化的制剂,选择了 d-α-生育酚聚氧乙烯 1000 琥珀酸酯:PEG400=8:2,并达到了目标载药量(200mg/mL)。该制剂形成了细小的乳状液/胶束(49.1nm),与常规制剂相比,形成和维持了更高水平的过饱和状态。在口服吸收试验中,优化制剂的血浆浓度-时间曲线下面积是喷射研磨制剂的 16.5 倍。
使用 HTFS 系统的逐步方法设计的高载药制剂提高了难溶性模型药物的口服吸收。